French biotechnology firm Abivax rejected media claims suggesting it had entered exclusive takeover discussions with pharmaceutical giant AstraZeneca.
The report, published by French outlet La Lettre, alleged Abivax had granted AstraZeneca exclusive access to confidential information to prepare a potential acquisition offer.
According to the report, the exclusivity period would last until March 23, allowing the British drugmaker time to formalize a takeover proposal.
However, an Abivax spokesperson firmly denied the claims, stating the company had not entered any such arrangement.
“We deny the information; these are unfounded rumors,” the spokesperson said in response to the report.
The company did not provide additional details but made clear no exclusive negotiations were underway with AstraZeneca.
The denial follows increased market speculation about potential consolidation in the biotech sector, particularly involving innovative drug developers.
For now, Abivax maintains that no takeover discussions have been formally agreed, dismissing the report as inaccurate.
